Immuron (NASDAQ:IMRN), an Australian-based biopharmaceutical company focused on oral immunotherapy, reported unaudited sales results for the third quarter ended March 31, 2026.
Global sales for the period reached AUD$1.5 million, a 16% increase compared to the prior-year period.
The results bring the company's year-to-date sales to AUD$5.7 million, representing a 7% increase over the first nine months of fiscal 2025.
The growth was primarily anchored by a robust performance in the Australian market, where Q3 sales rose 15% to AUD$0.9 million.
Management attributed the domestic momentum to several factors, including expanded digital and social media marketing, new store listings within pharmacy banner groups, and a notable uptick in international travel, particularly to Southeast Asian destinations.
In the United States, Q3 sales remained steady at AUD$0.5 million, a 1% increase year-over-year.
While year-to-date U.S. sales grew 10% to AUD$1.3 million, the company noted that the strengthening of the Australian dollar against the U.S. dollar acted as a translation headwind, partially masking organic growth driven by an enhanced presence on Amazon.com and localized social media initiatives.
The Canadian market showed significant sequential recovery, with Q3 sales reaching AUD$0.1 million.
While this represents a modest figure in absolute terms, it marks an 82% increase over the previous quarter.
The jump follows a strategic push into over 1,000 retail doors, including new listings with Jean Coutu in Quebec.
Despite the quarterly improvement, year-to-date Canadian sales remain down 65% due to a difficult year-over-year comparison against a high inventory pipeline fill in early 2025.